From the Guidelines
Semaglutide (Ozempic) and Semaglutide (Wegovy) differ in their FDA-approved uses and maximum dosages, with Ozempic primarily approved for type 2 diabetes management and Wegovy specifically approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. The main difference between the two is the maximum dosage, with Ozempic ranging from 0.25 mg to 2 mg weekly and Wegovy escalating from 0.25 mg to a higher maximum of 2.4 mg weekly 1. Both medications are GLP-1 receptor agonists that work by mimicking the incretin hormone GLP-1, which helps regulate blood sugar by increasing insulin secretion, decreasing glucagon secretion, slowing gastric emptying, and reducing appetite, leading to better glycemic control and weight loss 1. Some key points to consider when prescribing these medications include:
- The potential for weight loss, with studies showing that semaglutide can result in significant weight loss, with a mean weight loss of 14.9% at 68 weeks in the STEP 1 trial and 16.0% in the STEP 3 trial 1
- The importance of long-term use, as weight regain can occur after cessation of semaglutide treatment, with a mean weight regain of 11.6% of lost weight after 52 weeks of follow-up 1
- The potential for improved weight-related comorbidities, with semaglutide reducing the risk of cardiovascular events in adults with overweight or obesity without diabetes 1
- The potential side effects, including nausea, vomiting, diarrhea, and constipation, which can be mitigated with gradual dose titration 1. In terms of insurance coverage, Ozempic is typically covered under diabetes benefits, while Wegovy is covered under weight management benefits, which may be more limited 1. Overall, the choice between Semaglutide (Ozempic) and Semaglutide (Wegovy) will depend on the individual patient's needs and clinical profile, including their diagnosis, comorbidities, and insurance coverage.